Xylitol for Acute Otitis Media

Not reliably. For acute otitis media in children, xylitol cut infections in older Finnish day care trials but not in later ones, and the Italian pediatric guideline does not recommend it. A 2016 Cochrane review pooled three randomised trials in 1,826 healthy Finnish day care children and found moderate-quality evidence that xylitol in any form cut the share of children with an ear infection from 30% to around 22% (RR 0.75, 95% CI 0.65 to 0.88). The two early trials that found a benefit gave 8.4 g a day as gum or 10 g a day as syrup for two to three months.

The negative results are just as important. Xylitol did not reduce infections when it was given only once a cold had started (RR 1.13, 95% CI 0.83 to 1.53), and the review called the evidence in otitis-prone children inconclusive (RR 0.90, 95% CI 0.67 to 1.21; low quality). A 2007 trial of a simpler three-times-a-day schedule in 663 children found no effect, and a 2024 trial in 250 Canadian children found 6 infections on xylitol and 3 on placebo, too few events to show a benefit or rule one out. The review itself notes that the data came from few studies, most from the same research group. None of the trials reviewed for this page tested xylitol as a treatment for an active infection.

Xylitol was tested because of what it does to the bacteria that cause ear infections. In a 1995 laboratory study, 1% and 5% xylitol markedly reduced the growth of alpha-hemolytic streptococci, including Streptococcus pneumoniae, but not Haemophilus influenzae or Moraxella catarrhalis. In a 1998 study, 5% xylitol reduced the adherence of pneumococci to epithelial cells, and reduced the adherence of H. influenzae when both the cells and the bacteria were exposed to it.

Electron microscopy later showed that after 2 hours in xylitol the pneumococcal cell wall became more diffuse and the polysaccharide capsule ragged, which may affect how the bacteria stick and cause disease.

These are laboratory findings, and they do not all agree. A 2011 study found that 0.5% and 5% xylitol did not significantly reduce pneumococcal adherence to epithelial cells and suggested any benefit is more likely due to growth inhibition than to blocking adhesion. In the 1996 gum trial, pneumococcal carriage (17.4% to 28.2%) did not differ between children on xylitol and on sucrose.

None of these studies shows how much xylitol reaches a child's nasopharynx or middle ear from gum or syrup. The mechanism is a reason to run trials, not a reason to expect them to be positive, and the trials were mixed.

The two trials that found a benefit report only a daily dose: 8.4 g a day as chewing gum for two months in a 1996 trial of 306 children, and 8.4 g (gum) to 10 g (syrup) a day for three months in a 1998 trial of 857 children. A later trial describes the successful regimen as xylitol five times a day after each meal. The gum trial enrolled children with a mean age of about 5 years; chewing gum is a choking hazard for young children (CDC), so it is not a form to give toddlers.

Simpler schedules did not match it. Three times a day (9.6 g a day) failed to prevent infections in 663 healthy children, 5 g three times a day failed in 326 otitis-prone children, and syrup twice a day for six months did not help 250 children aged 1 to 5. No trial has established a dose to recommend, so the table below shows what was tested, not what to take.

The 1996 trial gave 306 Finnish day care children xylitol gum (8.4 g a day) or sucrose gum for two months. At least one ear infection occurred in 12.1% of the xylitol group and 20.8% of the sucrose group (P=0.04), and antimicrobial treatment was needed by 18.5% versus 28.9% (P=0.032). Most children had a history of recurrent infections.

The 1998 trial randomised 857 healthy day care children for three months. Ear infection occurred in 29% on xylitol syrup versus 41% on control syrup, a 30% decrease (95% CI 4.6% to 55.4%), and xylitol gum cut occurrence by 40% (CI 10.0% to 71.1%). The lozenge group's 20% decrease was not significant. These trials, together with a third in the same population that the review abstract does not name, make up the Cochrane pooled result (RR 0.75).

A 2002 trial of 1,277 children gave xylitol only during a respiratory infection and found no reduction in ear infections (20.5% on xylitol mixture versus 20.4% on control). A 2007 trial in 663 children gave 9.6 g a day three times a day for three months, and 28% on xylitol versus 30% on control had an infection. In 326 otitis-prone children aged 6 months to 5 years, 5 g of xylitol solution three times a day did not lower the risk (hazard ratio 0.88, 95% CI 0.61 to 1.3), and taking it faithfully did not change that.

The newest trial, in 250 Ontario children aged 1 to 5, gave xylitol syrup or sorbitol syrup twice a day for six months. There were 6 ear infections on xylitol and 3 on placebo (OR 2.04, 95% CI 0.43 to 12.92), and respiratory infections did not differ (rate ratio 0.88). The authors called it underpowered, so it can neither confirm nor rule out a modest benefit.

The uncontrolled 2024 nasal-spray pilot in 68 children reported episodes falling from 4.12 to 1.06 per three months, but there was no control group, and episodes stayed low after the spray stopped (0.79 per three months). Without a control group, the fall cannot be separated from natural variation or regression to the mean, so this does not show the spray works. Missing from the record are an independent replication of the five-times-a-day schedule, longer follow-up, and any trial in treatment.

For other prevention options, a Cochrane review of probiotics found 23% fewer children with an ear infection overall (RR 0.77, 95% CI 0.63 to 0.93) but no difference in otitis-prone children (RR 0.97). One trial of 116 otitis-prone children found fewer with an infection on vitamin D 1,000 IU a day (26 versus 38; P=0.03). The 2019 Italian guideline does not recommend xylitol, probiotics or vitamin D, and instead supports removing risk factors and vaccination.

In children, xylitol was generally tolerated. In a 3-month trial of 120 children aged 6 to 36 months, 5 g three times a day or 7.5 g once daily had excessive gas or diarrhoea in 10% to 27% of children in a given month, a rate that did not differ from placebo. In the 2024 trial of syrup twice a day, diarrhoea affected 34% on xylitol and 28% on placebo, and the Cochrane review found no significant differences in abdominal discomfort and rash among reasons for dropping out.

The limit is the bowel. In healthy adults, a single 35 g or 50 g dose in water caused watery stools, and the single dose that did not cause diarrhoea was about 0.37 to 0.42 g per kg of body weight. For scale, that works out to roughly 5.5 g for a 15 kg child, though the threshold comes from adults and may not transfer. A 2024 study in cardiac patients linked higher blood xylitol to heart events (hazard ratio 1.57) and a xylitol drink raised platelet reactivity in 10 volunteers; this concerns adults, and its relevance to children's doses is unknown. See the xylitol page for more.

The CDC advises that low-calorie sweeteners are not recommended for infants and young children, and the tolerability data above come from one small 3-month trial. The CDC also lists chewing gum among the choking hazards for young children, so gum is not an option for toddlers.

The trials and guidelines reviewed report no specific drug interactions. The practical risk is substitution: xylitol has not been shown to treat an infection, so it should never delay seeing a clinician for ear pain, fever or ear discharge.